NCT05294458View on ClinicalTrials.gov

A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions

Non-alcoholic SteatohepatitisType 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease

Interventions

DRUG

cotadutide solution for injection

cotadutide solution for injection

Trial Locations (1)

NG11 6JS

Research Site, Ruddington

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Quotient Sciences

INDUSTRY

lead

AstraZeneca

INDUSTRY